Markets

The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

For Immediate Release

Chicago, IL -November 15, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ChevronCVX , NovartisNVS , QualcommQCOM , TJXTJX and DeereDE .

Here are highlights from Wednesday's Analyst Blog:

Top Analyst Reports for Chevron, Novartis and Qualcomm

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron, Novartis and Qualcomm. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Chevron 's shares have declined 7.9% so far this year, underperforming the Zacks Integrated Oil industry's 5.8% decrease. However, Chevron's Q3 earnings more than doubled year over year and was ahead of analysts' expectations. Cash flow was at its highest level in nearly 5 years, while upstream production hit a record.

Chevron's existing oil and gas development project pipeline is among the best in the industry, targeting volume growth of around 7% in 2018 thanks to planned expansion in the Permian Basin. The oil supermajor pumped 80% more out of the West Texas shale play in the quarter compared with the same period last year, with production set to soar in coming years.

Moreover, the enormous increase in cash flow enabled Chevron to repurchase $750 million of its own shares. Yet there are worries over a drop in its downstream earnings due to weak international margins that once again cut into overall gains from rising E&P income. Hence, investors are advised to wait for a better entry point before buying shares of Chevron.

Shares of Novartis have outperformed the Zacks Large-Cap Pharmaceuticals industry (+14% vs. +12%), in the last six months. Novartis beat sales estimates in the third quarter on strong performance of Cosentyx and Entresto. The label expansion of oncology drugs also boost the top line.

Novartis has a strong oncology portfolio including drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali, which continue to boost sales. Novartis restructured its business and plans to focus on becoming a core drug-focused company, powered by data and digital technologies. The company is looking to solidify its presence in the gene-therapy space. It acquired U.S.-based clinical stage gene therapy company, AveXis, Inc.

Novartis also announced that it will acquire Endocyte to further strengthen its pipeline. However, generic division Sandoz continues to face pricing pressure. The division also suffered a blow when the FDA issued a CRL to its generic Advair Diskus.

Qualcomm 's shares have lost 17.5% over the past year vs +6% for the Zacks Wireless Equipment industry. Regulatory disputes and aggressive competition in the mobile phone chipset market will likely hurt Qualcomm in future. However, Qualcomm reported healthy fourth-quarter fiscal 2018 results backed by proper execution of its strategic priorities to drive technology and product leadership.

The company has been trying to retain its leadership in 5G, chipset market and mobile connectivity with multiple technological achievements and innovative product launches. It expects growth from its China business in fiscal 2019, particularly in the second half.

While Qualcomm expanded its leadership to the high tiers with Snapdragon 700, its Snapdragon 800 solutions will continue defining the premium tier benchmarks. The product mix is improving in the China region and key Qualcomm China-based customers are gaining share globally, auguring well for its future business growth.

Other noteworthy reports we are featuring today include TJX and Deere.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novartis AG (NVS): Free Stock Analysis Report

QUALCOMM Incorporated (QCOM): Free Stock Analysis Report

Deere & Company (DE): Free Stock Analysis Report

Chevron Corporation (CVX): Free Stock Analysis Report

The TJX Companies, Inc. (TJX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

QCOM CVX DE NVS TJX

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More